| Title: | Relationship between preexisting anti-varicella-zoster virus (VZV) antibody and clinical VZV reactivation in hematopoietic stem cell transplantation recipients. |
| Authors: | Onozawa, Masahiro Browse this author |
| Hashino, Satoshi Browse this author →KAKEN DB |
| Takahata, Mutsumi Browse this author |
| Fujisawa, Fumie Browse this author |
| Kawamura, Takahito Browse this author |
| Nakagawa, Masao Browse this author |
| Kahata, Kaoru Browse this author |
| Kondo, Takeshi Browse this author →KAKEN DB |
| Ota, Shuichi Browse this author |
| Tanaka, Junji Browse this author |
| Imamura, Masahiro Browse this author |
| Asaka, Masahiro Browse this author |
| Issue Date: | Dec-2006 |
| Publisher: | the American Society for Microbiology |
| Journal Title: | Journal of Clinical Microbiology |
| Volume: | 44 |
| Issue: | 12 |
| Start Page: | 4441 |
| End Page: | 4443 |
| Publisher DOI: | 10.1128/JCM.01312-06 |
| PMID: | 17035500 |
| Abstract: | Reactivation of latent varicella zoster virus (VZV), presenting as localized zoster or as disseminated infection, is a common and potentially serious complication in hematopoietic stem cell transplantation (HSCT) recipients. We retrospectively studied anti-VZV IgG titers by the immune adherence hemagglutination method after HSCT and VZV DNA by real-time PCR during clinical VZV reactivation using cryopreserved serum samples. No significant difference was found between anti-VZV titers in 13 patients with VZV infection (localized zoster in 11 patients and disseminated zoster in 2 patients) and those in 13 subjects without VZV infection at each time point after HSCT. Pre-existing anti-VZV titers of disseminated zoster cases tended to be lower than those of localized zoster cases (P=0.10). Serum VZV-DNA copy numbers at onset of disseminated zoster cases tended to be higher than those of localized zoster cases (P=0.09). A strong inverse correlation was found between pre-existing anti-VZV titer and serum VZV-DNA at onset (r=-0.90, P=0.006). In HSCT recipients, pre-existing antibody does not prevent development of VZV reactivation but may contribute to decreased viral load at onset, resulting in a mild clinical course. |
| Rights: | Copyright © American Society for Microbiology |
| Type: | article (author version) |
| URI: | http://hdl.handle.net/2115/17172 |
| Appears in Collections: | 北海道大学病院 (Hokkaido University Hospital) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
|
